期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 24, 期 5, 页码 823-834出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2005.03.8471
关键词
-
类别
资金
- NCI NIH HHS [P01 CA103985] Funding Source: Medline
- NIBIB NIH HHS [EB002114] Funding Source: Medline
This article reviews the methods of pretargeting, which involve separating the targeting antibody from the subsequent delivery of an imaging or therapeutic agent that binds to the tumor-localized antibody. This provides enhanced tumor: background ratios and the delivery of a higher therapeutic dose than when antibodies are directly conjugated with radionuclides, as currently practiced in cancer radioimmunotherapy. We describe initial promising clinical results using streptavidin-antibody constructs with biotin-radionuclide conjugates in the treatment of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the therapy of tumors expressing carcinoembryonic antigen, such as medullary thyroid and small-cell lung cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据